The holy grail of antithrombotic therapy has long been separating clot prevention from bleeding risk — a trade-off that has frustrated cardiologists for decades. A new large-scale trial published in the New England Journal of Medicine suggests that targeting factor XIa, a coagulation pathway component, may finally offer a meaningful step toward that goal in patients recovering from acute coronary syndrome (ACS).
The trial evaluated milvexian, an oral factor XIa inhibitor, added on top of standard dual antiplatelet therapy (DAPT) in ACS patients. Factor XIa sits at a critical junction in the intrinsic coagulation cascade — involved in pathological thrombus amplification but with a comparatively limited role in hemostasis, the body's normal wound-sealing response. The study enrolled thousands of post-ACS patients and assessed rates of major adverse cardiovascular events including recurrent myocardial infarction and ischemic stroke, alongside bleeding endpoints. Results showed a reduction in ischemic outcomes with milvexian at select doses without a statistically significant increase in major bleeding — a combination that has eluded earlier anticoagulant strategies.
This finding fits into an accelerating wave of interest in contact pathway inhibition. Factor XIa has emerged as arguably the most attractive anticoagulation target of the past decade, with the logic supported by epidemiological observations that individuals with congenital factor XI deficiency have lower rates of ischemic stroke and venous thromboembolism without a clear hemostatic deficit. Prior early-phase trials of milvexian and the rival factor XIa inhibitor asundexian showed signal, but phase III cardiovascular outcomes data were scarce until now. The key limitation is that triple antithrombotic therapy — DAPT plus an anticoagulant — historically increases bleeding substantially, so long-term safety surveillance beyond trial conditions remains essential. If these findings replicate across broader ACS populations, factor XIa inhibition could reshape post-ACS secondary prevention protocols within this decade.